These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 22532634)

  • 1. A CD4 T cell gene signature for early rheumatoid arthritis implicates interleukin 6-mediated STAT3 signalling, particularly in anti-citrullinated peptide antibody-negative disease.
    Pratt AG; Swan DC; Richardson S; Wilson G; Hilkens CM; Young DA; Isaacs JD
    Ann Rheum Dis; 2012 Aug; 71(8):1374-81. PubMed ID: 22532634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IL-6-driven STAT signalling in circulating CD4+ lymphocytes is a marker for early anticitrullinated peptide antibody-negative rheumatoid arthritis.
    Anderson AE; Pratt AG; Sedhom MA; Doran JP; Routledge C; Hargreaves B; Brown PM; Lê Cao KA; Isaacs JD; Thomas R
    Ann Rheum Dis; 2016 Feb; 75(2):466-73. PubMed ID: 25649145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of STAT3-regulated genes in circulating CD4+ T cells discriminates rheumatoid arthritis independently of clinical parameters in early arthritis.
    Anderson AE; Maney NJ; Nair N; Lendrem DW; Skelton AJ; Diboll J; Brown PM; Smith GR; Carmody RJ; Barton A; Isaacs JD; Pratt AG
    Rheumatology (Oxford); 2019 Jul; 58(7):1250-1258. PubMed ID: 30753680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autoantibodies to cyclic citrullinated peptide 2 (CCP2) are superior to other potential diagnostic biomarkers for predicting rheumatoid arthritis in early undifferentiated arthritis.
    Kudo-Tanaka E; Ohshima S; Ishii M; Mima T; Matsushita M; Azuma N; Harada Y; Katada Y; Ikeue H; Umeshita-Sasai M; Miyatake K; Saeki Y
    Clin Rheumatol; 2007 Oct; 26(10):1627-33. PubMed ID: 17286215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early prediction of rheumatoid arthritis by magnetic resonance imaging in the absence of anti-cyclic citrullinated peptide antibodies and radiographic erosions in undifferentiated inflammatory arthritis patients: a prospective study.
    Ji L; Li G; Xu Y; Zhou W; Zhang Z
    Int J Rheum Dis; 2015 Nov; 18(8):859-65. PubMed ID: 25483781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis.
    van der Linden MP; van der Woude D; Ioan-Facsinay A; Levarht EW; Stoeken-Rijsbergen G; Huizinga TW; Toes RE; van der Helm-van Mil AH
    Arthritis Rheum; 2009 Aug; 60(8):2232-41. PubMed ID: 19644872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD4 T-cell transcriptome analysis reveals aberrant regulation of STAT3 and Wnt signaling pathways in rheumatoid arthritis: evidence from a case-control study.
    Ye H; Zhang J; Wang J; Gao Y; Du Y; Li C; Deng M; Guo J; Li Z
    Arthritis Res Ther; 2015 Mar; 17(1):76. PubMed ID: 25880754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IL-22+ CD4+ T cells in patients with rheumatoid arthritis.
    Zhao L; Jiang Z; Jiang Y; Ma N; Zhang Y; Feng L; Wang K
    Int J Rheum Dis; 2013 Oct; 16(5):518-26. PubMed ID: 24164838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The activity of JAK-STAT pathways in rheumatoid arthritis: constitutive activation of STAT3 correlates with interleukin 6 levels.
    Isomäki P; Junttila I; Vidqvist KL; Korpela M; Silvennoinen O
    Rheumatology (Oxford); 2015 Jun; 54(6):1103-13. PubMed ID: 25406356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The diagnostic utility of matrix metalloproteinase-3 and high-sensitivity C-reactive protein for predicting rheumatoid arthritis in anti-cyclic citrullinated peptide antibody-negative patients with recent-onset undifferentiated arthritis.
    Hiura K; Iwaki-Egawa S; Kawashima T; Fujisawa S; Takeda T; Komori H; Watanabe Y
    Rheumatol Int; 2013 Sep; 33(9):2309-14. PubMed ID: 23503938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prevalence and diagnostic performance of anti-cyclic citrullinated peptide antibody in rheumatoid arthritis: the predictive and discriminative ability of serum antibody level in recognizing rheumatoid arthritis.
    Heidari B; Firouzjahi A; Heidari P; Hajian K
    Ann Saudi Med; 2009; 29(6):467-70. PubMed ID: 19847085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autoantibodies to two novel peptides in seronegative and early rheumatoid arthritis.
    De Winter LM; Hansen WL; van Steenbergen HW; Geusens P; Lenaerts J; Somers K; Stinissen P; van der Helm-van Mil AH; Somers V
    Rheumatology (Oxford); 2016 Aug; 55(8):1431-6. PubMed ID: 27094600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative analysis of autoantibodies targeting peptidylarginine deiminase type 4, mutated citrullinated vimentin and cyclic citrullinated peptides in rheumatoid arthritis: associations with cytokine profiles, clinical and genetic features.
    Reyes-Castillo Z; Palafox-Sánchez CA; Parra-Rojas I; Martínez-Bonilla GE; del Toro-Arreola S; Ramírez-Dueñas MG; Ocampo-Bermudes G; Muñoz-Valle JF
    Clin Exp Immunol; 2015 Nov; 182(2):119-31. PubMed ID: 26149185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new bioassay for measuring the strength of IL-6/STAT3 signal inhibition by tocilizumab in patients with rheumatoid arthritis.
    Saito S; Suzuki K; Yoshimoto K; Kaneko Y; Matsumoto Y; Yamaoka K; Takeuchi T
    Arthritis Res Ther; 2017 Oct; 19(1):231. PubMed ID: 29041951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An investigation of the added value of an ACPA multiplex assay in an early rheumatoid arthritis setting.
    van Heemst J; Trouw LA; Nogueira L; van Steenbergen HW; van der Helm-van Mil AH; Allaart CF; Serre G; Holmdahl R; Huizinga TW; Toes RE; van der Woude D
    Arthritis Res Ther; 2015 Oct; 17():276. PubMed ID: 26437716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic utility of anti-cyclic citrullinated peptide antibodies for very early rheumatoid arthritis.
    Matsui T; Shimada K; Ozawa N; Hayakawa H; Hagiwara F; Nakayama H; Sugii S; Ozawa Y; Tohma S
    J Rheumatol; 2006 Dec; 33(12):2390-7. PubMed ID: 16924694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epitope spreading of the anti-citrullinated protein antibody response occurs before disease onset and is associated with the disease course of early arthritis.
    van der Woude D; Rantapää-Dahlqvist S; Ioan-Facsinay A; Onnekink C; Schwarte CM; Verpoort KN; Drijfhout JW; Huizinga TW; Toes RE; Pruijn GJ
    Ann Rheum Dis; 2010 Aug; 69(8):1554-61. PubMed ID: 20448290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of HLA-DR3 with anti-cyclic citrullinated peptide antibody-negative rheumatoid arthritis.
    Verpoort KN; van Gaalen FA; van der Helm-van Mil AH; Schreuder GM; Breedveld FC; Huizinga TW; de Vries RR; Toes RE
    Arthritis Rheum; 2005 Oct; 52(10):3058-62. PubMed ID: 16200610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive value of antibodies to cyclic citrullinated peptide in patients with very early inflammatory arthritis.
    Raza K; Breese M; Nightingale P; Kumar K; Potter T; Carruthers DM; Situnayake D; Gordon C; Buckley CD; Salmon M; Kitas GD
    J Rheumatol; 2005 Feb; 32(2):231-8. PubMed ID: 15693082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic performance of anti-cyclic citrullinated peptide and rheumatoid factor in patients with rheumatoid arthritis.
    Chang PY; Yang CT; Cheng CH; Yu KH
    Int J Rheum Dis; 2016 Sep; 19(9):880-6. PubMed ID: 25940989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.